The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

George Washington University600 enrolled

Overview

The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.

Study Type

OBSERVATIONAL

Enrollment

600

Conditions

Scleroderma

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age \>18 years * Able to give informed consent. * Diagnosed with scleroderma or with positive autoantibodies Exclusion Criteria: * \< 18 years old

Locations (1)

Victoria K Shanmugam

Washington D.C., District of Columbia, United States

Outcomes

Primary Outcomes

Modified Rodnan Skin Score

Time frame: 10 years

Secondary Outcomes

Medsger Severity Score

Time frame: 10 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.